−0.0322EUR
−2.03 MEUR
623.37 KEUR
About S2MEDICAL AB SER. B
Sector
Industry
CEO
Petter Sivlér
Website
Headquarters
Linköping
Founded
2013
ISIN
SE0011725084
FIGI
BBG00N8TWGZ8
S2Medical AB engages in research and development in biotechnology. It develops and sells wound healing products for the entire wound healing process focusing on burns and chronic wounds. It offers wound debridement, blood stilling, skin grafting, tissue substitutes, bandage, and antimicrobial products. The company was founded by Petter Sivlér and Mårten Skog on June 13, 2013 and is headquartered in Linköping, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange S2MEDICAL AB B stocks are traded under the ticker S21.
Yes, you can track S2MEDICAL AB B financials in yearly and quarterly reports right on TradingView.
S21 net income for the last quarter is −341.87 K EUR, while the quarter before that showed −522.82 K EUR of net income which accounts for 34.61% change. Track more S2MEDICAL AB B financial stats to get the full picture.
No, S21 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, S21 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade S2MEDICAL AB B stock right from TradingView charts — choose your broker and connect to your account.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. S2MEDICAL AB B EBITDA is −1.26 M EUR, and current EBITDA margin is −202.32%. See more stats in S2MEDICAL AB B financial statements.